Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results

Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.